The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2024

Filed:

Apr. 05, 2022
Applicant:

Whitehead Institute for Biomedical Research, Cambridge, MA (US);

Inventors:

Rudolf Jaenisch, Brookline, MA (US);

Xin Tang, Quincy, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/05 (2006.01); A61K 31/404 (2006.01); A61K 31/4525 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/519 (2006.01); A61P 25/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/05 (2013.01); A61K 31/404 (2013.01); A61K 31/4525 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/519 (2013.01); A61P 25/28 (2018.01);
Abstract

Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome (RTT), a severe neurodevelopmental disorder caused by mutations in the X-linked gene Methyl CpG binding Protein 2 (MECP2), has been linked to deficits in KCC2. The disclosure reports the use of CRISPR/Cas9 genome-editing technology to generate stem cell-derived, genetically defined KCC2 reporter human neurons for large-scale compound screening. This screening platform has been utilized to identify a number of small molecule compounds that are capable of enhancing KCC2 expression in both wild-type and RTT neurons, as well as organotypical brain slices cultured from wild-type mice. These first-in class compounds may be applied as a novel therapeutic approach to restore the impaired balance between excitation and inhibition observed in neurological diseases, psychiatric disorders, and central nervous system injuries.


Find Patent Forward Citations

Loading…